Invention Grant
- Patent Title: Use of cannabidiol in treatment of pulmonary hypertension
-
Application No.: US16630428Application Date: 2017-07-18
-
Publication No.: US11666542B2Publication Date: 2023-06-06
- Inventor: Ke Zhang , Xin Tan , Zhaohui Yu , Xiangdong Li
- Applicant: DEYI PHARMARMACEUTICAL LTD.
- Applicant Address: CN Kunming
- Assignee: DEYI PHARMARMACEUTICAL LTD.
- Current Assignee: DEYI PHARMARMACEUTICAL LTD.
- Current Assignee Address: CN Kunming
- Agency: Platinum Intellectual Property PC
- International Application: PCT/CN2017/093367 2017.07.18
- International Announcement: WO2019/014851A 2019.01.24
- Date entered country: 2020-01-10
- Main IPC: A61K31/05
- IPC: A61K31/05 ; A61P9/12 ; A61P11/00 ; A61K31/191 ; A61K31/192 ; A61K31/4985 ; A61K31/506 ; A61K31/519 ; A61K31/53 ; A61K36/185 ; A61K45/06

Abstract:
The present invention belongs to the field of medicine, and relates to use of cannabidiol (CBD) in the treatment of pulmonary arterial hypertension. The CBD can be used as the only active ingredient or combined with other active ingredients to prepare a medicament for treating pulmonary arterial hypertension. Specifically, the present invention relates to use of any one selected from (1) to (3) in the preparation of a medicament for treating and/or preventing pulmonary arterial hypertension: (1) CBD, (2) a plant extract containing the CBD; and preferably, the plant extract is a cannabis extract, and (3) a pharmaceutical composition containing the CBD and one or more pharmaceutically acceptable adjuvants. In the present invention, upon experimental researches, it has found that the CBD has the function of inhibiting pulmonary arterial hypertension, and is especially suitable for treating the pulmonary arterial hypertension caused by hypoxemia.
Information query